Clinical trials: Cancer Anorexia-Cachexia Syndrome
Cachexia-Anorexia Syndrome, Cachexia; Cancer
A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia.
- Trial name
- NCT07890324
- Testing
- SXRN Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Jiangsu Guiqiong Pharmaceutical Co., Ltd.
Cachexia-Anorexia Syndrome, Solid Tumor Malignancies
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia
This is a clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SXRN Injection in cancer patients with anorexia-cachexia.
- Trial name
- NCT07231120
- Testing
- SXRN Injection
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
Cancer Cachexia, Atypical Anorexia Nervosa
Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients
The main purpose in the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) is to prolong life and to improve quality of life (QoL) as far as possible.
- Trial name
- NCT02359123
- Testing
- Cannabics capsules
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Cannabics Pharmaceuticals Inc.
Cachexia; Cancer, Cachexia
OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of the OLE study is to evaluate the long-term safety and tolerability of rilogrotug treatment in participants who have completed the parent study and are eligible to receive continued treatment.
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH-OLE (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 400 people
- Sponsor
- AVEO Pharmaceuticals, Inc.